Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
B 31.03 -1.52% -0.48
FDMT closed down 1.52 percent on Monday, March 18, 2024, on 60 percent of normal volume.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
Multiple of Ten Bullish Other -1.52%
Above Upper BB Strength -1.52%
Upper Bollinger Band Touch Strength -1.52%
Gapped Down Weakness -1.52%
Earnings Movers Other 5.65%
Outside Day Range Expansion 5.65%
NR7 Range Contraction 5.54%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 8 hours ago
Up 1% about 10 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Down 3% about 12 hours ago
Down 2 % about 12 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Emerging Technologies Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Of The Human Retina Gene Therapy Products

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.6134
52 Week Low 9.44
Average Volume 1,292,353
200-Day Moving Average 17.91
50-Day Moving Average 24.53
20-Day Moving Average 28.65
10-Day Moving Average 29.28
Average True Range 1.89
RSI (14) 62.26
ADX 38.61
+DI 34.60
-DI 12.94
Chandelier Exit (Long, 3 ATRs) 26.69
Chandelier Exit (Short, 3 ATRs) 31.68
Upper Bollinger Bands 31.37
Lower Bollinger Band 25.93
Percent B (%b) 0.94
BandWidth 19.00
MACD Line 1.51
MACD Signal Line 1.53
MACD Histogram -0.0231
Fundamentals Value
Market Cap 1.53 Billion
Num Shares 49.3 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -11.71
Price-to-Sales 62.23
Price-to-Book 4.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.24
Resistance 3 (R3) 33.28 32.60 32.87
Resistance 2 (R2) 32.60 32.04 32.57 32.74
Resistance 1 (R1) 31.81 31.69 31.47 31.77 32.62
Pivot Point 31.13 31.13 30.96 31.10 31.13
Support 1 (S1) 30.34 30.57 30.00 30.30 29.44
Support 2 (S2) 29.66 30.22 29.63 29.32
Support 3 (S3) 28.87 29.66 29.19
Support 4 (S4) 28.83